Impacto do consumo regular de ovos e ovos fortificados com nutrientes na condição de eczema em indivíduos de Cingapura
Impacto do consumo regular de ovos e ovos fortificados com nutrientes na condição de eczema em indivíduos com eczema em Cingapura
The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in Singapore individuals with eczema. The investigators hypothesize that egg consumption will improve eczema condition and nutrients fortified egg consumption will improve further improvements when compared to standard egg consumption in individuals with eczema
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is a double-blind, randomized, parallel study and all subjects will complete a 12-week study period. Subjects will be tasked to consume nutrients-fortified eggs and regular eggs daily for 12 weeks. After which, subjects are assessed for changes in carotenoid status, antioxidant and anti-inflammatory biomarkers, skin and eye health measurements, and other biomarkers of health.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Singapore
-
Singapore, Singapore, Cingapura, 117550
- Department of Food Science and Techonology, Block S13
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- English-literate and able to give informed consent in English
- Male and female participants, aged between 21 and 59 inclusive
- Healthy individuals with no underlying condition or on regular medication
- BMI between 18.5-25 kg/m2
- Mild to moderate severity of eczema, which will also be determined using our questionnaires during the screening visit
Exclusion Criteria:
- Significant change in body weight (3 kg or more) in the past 3 months
- Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
- Known food allergy to eggs
- Taking dietary supplements which may impact the study results
- Having gastrointestinal disorders not suitable for the study
- Current smokers
- Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider, or 45ml of distilled spirit
- Taking lipid-lowering and blood pressure-controlling medications for less than 3 years
- Pregnant or lactating women, or planning to conceive in the next 6 months
- Unwilling to stop the medication of eczema during the study, either topical creams or oral medications
- Hierarchical link (professional and familial ties) with the research team members
- Participating in another clinical study
- Having blindness in one eye or more, eye diseases, retinal/lens/optical nerve surgery, or other eye conditions that may impact the study results
- Low-quality macular pigment optical density results were determined during the screening visit.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Regular egg with habitual diet
Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 regular egg/day for 12 weeks. |
Consumption of regular egg with habitual diet |
|
Experimental: Nutrient-fortified egg with habitual diet
Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 nutrient-fortified egg/day for 12 weeks. |
Consumption of nutrient-fortified eggs with habitual diet |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Skin questionnaires - SCORing Atopic Dermatitis (SCORAD) Index
Prazo: Week 0, week 3, week 6, week 9, week 12
|
SCORing Atopic Dermatitis (SCORAD) Index is a clinical tool used to assess the severity of atopic dermatitis (AD), also known as eczema. This index can estimate participants' body surface area affected by burns (extent - A: percentage of body surface area affected), Intensity (B: clinical signs are assessed and scored on a scale from 0 (absent) to 3 (severe)), Subjective Symptoms (C: itch, sleep disturbance are evaluated based on the participants' report over the past three days, each scored on a scale from 0 (no symptom) to 10(severe symptom)). The SCORAD index is calculated using the following formula: SCORAD=A/5+7B/2+C Interpretation Mild atopic dermatitis: SCORAD < 25 Moderate atopic dermatitis: SCORAD 25-50 Severe atopic dermatitis: SCORAD > 50 |
Week 0, week 3, week 6, week 9, week 12
|
|
Skin questionnaires - Eczema Area and Severity Index (EASI) scoring system
Prazo: Week 0, week 3, week 6, week 9, week 12
|
EASI evaluates the extent and severity of eczema in four body regions: the head and neck, the trunk, the upper limbs, and the lower limbs. The EASI score ranges from 0 to 72, with higher scores indicating more severe eczema: 0: No eczema 1-7: Mild eczema 8-21: Moderate eczema 22-50: Severe eczema 51-72: Very severe eczema |
Week 0, week 3, week 6, week 9, week 12
|
|
Skin questionnaires - Dermatology life quality index (DLQI)
Prazo: Week 0, week 3, week 6, week 9, week 12
|
DLQI is a dermatology-specific instrument used to measure the impact of skin diseases on patients' quality of life. Which assessed disease impact, monitor treatment effectiveness, guide clinical decision-making. Interpretation of Scores: 0-1: No effect on patient's life 2-5: Small effect on patient's life 6-10: Moderate effect on patient's life 11-20: Very large effect on patient's life 21-30: Extremely large effect on patient's life |
Week 0, week 3, week 6, week 9, week 12
|
|
Skin measurement - eczema related
Prazo: Week 0, week 3, week 6, week 9, week 12
|
Skin hydration - units arbitrary Corneometer®. Transepidermal water loss - units gram/hour. Sebum level - unit µg/cm2. Skin pH level - skin pH meter. Skin tape stripping: stratum corneum components assessed by immune dot blots |
Week 0, week 3, week 6, week 9, week 12
|
|
Skin carotenoids status
Prazo: Week 0, week 3, week 6, week 9, week 12
|
Skin carotenoids concentration can be measured by Resonance Raman Spectroscopy, unit is skin carotenoid score, higher score means optimal, lower score means poor condition of skin carotenoids. |
Week 0, week 3, week 6, week 9, week 12
|
|
Blood carotenoids levels
Prazo: Week 0, week 6, week 12
|
Blood carotenoids levels can be measured by High-Performance Liquid Chromatography, unit is μmol/L. |
Week 0, week 6, week 12
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Eye health - Macular Pigment Optical Density
Prazo: Week 0, week 3, week 6, week 9, week 12
|
A measurement of macular pigment of the eye using a heterochromatic flicker photometry device. The measurements are in arbitrary units. |
Week 0, week 3, week 6, week 9, week 12
|
|
Eye health - Visual acuity
Prazo: Week 0, week 3, week 6, week 9, week 12
|
Participants will read out letters on a ETDRS LogMAR chart at a fixed distance where letters becomes smaller as it goes down the chart. Tests results will be recorded in number of letters read, where the more letters the better the outcome. |
Week 0, week 3, week 6, week 9, week 12
|
|
Eye health - Photostress recovery time
Prazo: Week 0, week 3, week 6, week 9, week 12
|
An ophthalmoscope will be used to shine a light into the participants eye for 10 seconds, and participants will be required to read letters off a chart the moment their vision returns to normal. The faster the recovery time, the better the outcome. Units will be in seconds |
Week 0, week 3, week 6, week 9, week 12
|
|
Visual function questionnaire 25
Prazo: Week 0, week 3, week 6, week 9, week 12
|
A questionnaire to for participants to self-evaluate their perception of their current eye health based on general vision, ocular pain, near activities, distance activities, vision specific functions, driving, color vision and peripheral vision. The best possible score is 100 and worst possible score is 0. |
Week 0, week 3, week 6, week 9, week 12
|
|
Concentration of tumour necrosis factor-α
Prazo: Week 0, week 6, week 12
|
The blood obtained from the participants will be processed for storage. Tumor necrosis factor-α results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits. |
Week 0, week 6, week 12
|
|
Concentration of interleukin-6
Prazo: Week 0, week 6, week 12
|
The blood obtained from the participants will be processed for storage. Interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits. |
Week 0, week 6, week 12
|
|
Concentration of high-sensitivity C-reactive protein
Prazo: Week 0, week 6, week 12
|
The blood obtained from the participants will be processed for storage. High-sensitivity C-reactive protein results will be obtained and presented in mg/L by commercial lab testing. |
Week 0, week 6, week 12
|
|
Concentration of fasting blood glucose
Prazo: Week 0, week 6, week 12
|
Fasting blood glucose will be measured using commercial lab testing using participants' blood, units will be in mmol/L. |
Week 0, week 6, week 12
|
|
Concentration of malondialdehyde
Prazo: Week 0, week 6, week 12
|
The blood obtained from the participants will be processed for storage. Analyses of malondialdehyde using commercially available enzyme-linked immunosorbent assay kits. Units for malondialdehyde will be in ng/L according to assay kit instructions. |
Week 0, week 6, week 12
|
|
Concentration of 8-isoprostaglandin-F2α
Prazo: Week 0, week 6, week 12
|
The blood obtained from the participants will be processed for storage. Analyses of 8-isoprostaglandin-F2α using commercially available enzyme-linked immunosorbent assay kits. Units for 8-isoprostaglandin-F2α will be in µmol/L according to assay kit instructions. |
Week 0, week 6, week 12
|
|
Concentration of insulin
Prazo: Week 0, week 6, week 12
|
Fasting blood insulin will be measured using commercial lab testing using participants' blood, units in μU/L. |
Week 0, week 6, week 12
|
|
Percentage of glycated hemoglobin
Prazo: Week 0, week 6, week 12
|
Glycated hemoglobin will be measured using commercial lab testing from participant's blood, units in percent. |
Week 0, week 6, week 12
|
|
Skin advanced glycation end products levels
Prazo: Week 0, week 3, week 6, week 9, week 12
|
Measurement of skin advanced glycation end products level using a skin autofluorescence device, where participants wlll be instructed to place their forearm over the device and a light will be shone and a reading can be captured by detecting fluorescence. The results will be presented as arbitrary units. |
Week 0, week 3, week 6, week 9, week 12
|
|
Blood advanced glycation end products levels
Prazo: Week 0, week 3, week 6, week 9, week 12
|
Participants will have their blood drawn by medical professionals at the Occupational Health Clinic. The blood will be processed and stored. Measurements will be done using ultra-performance liquid chromatography coupled with mass spectrometry techniques to determine the levels of advanced glycation end products. Units will be in μg/mL. |
Week 0, week 3, week 6, week 9, week 12
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Dietary assessment
Prazo: Week 0, week 3, week 6, week 9, week 12
|
3-day food record will be used to assess participants' dietary intake for two weekdays and one weekend day before each clinical visit. |
Week 0, week 3, week 6, week 9, week 12
|
|
Measurement of height
Prazo: Week 0, week 3, week 6, week 9, week 12
|
Height will be measured using height-weight scale and units will be in cm. |
Week 0, week 3, week 6, week 9, week 12
|
|
Measurement of blood pressure
Prazo: Week 0, week 3, week 6, week 9, week 12
|
A blood pressure monitoring device available commercially will be used be to measure their systolic and diastolic blood pressure. Unit is mmHg. |
Week 0, week 3, week 6, week 9, week 12
|
|
Measurement of weight
Prazo: Week 0, week 3, week 6, week 9, week 12
|
Weight will be measured using height-weight scale and units will be in kg. |
Week 0, week 3, week 6, week 9, week 12
|
|
Measurement of waist circumference
Prazo: Week 0, week 3, week 6, week 9, week 12
|
Waist circumference will be measured using a measuring tape by a trained personnel, units in cm. |
Week 0, week 3, week 6, week 9, week 12
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Jung Eun Kim, PhD, RD, National University of Singapore
Publicações e links úteis
Publicações Gerais
- Imai A, Oda Y, Ito N, Seki S, Nakagawa K, Miyazawa T, Ueda F. Effects of Dietary Supplementation of Astaxanthin and Sesamin on Daily Fatigue: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study. Nutrients. 2018 Feb 28;10(3):281. doi: 10.3390/nu10030281.
- Wilson LM, Tharmarajah S, Jia Y, Semba RD, Schaumberg DA, Robinson KA. The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis. Adv Nutr. 2021 Dec 1;12(6):2244-2254. doi: 10.1093/advances/nmab071.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Genéticas, Congênitas
- Doenças do sistema imunológico
- Hipersensibilidade, Imediata
- Hipersensibilidade
- Doenças de pele
- Doenças de Pele Genéticas
- Doenças de Pele, Eczematosas
- Dermatite
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças da Pele e do Tecido Conjuntivo
- Dermatite Atópica
- Eczema
Outros números de identificação do estudo
Outros números de identificação do estudo
- S26
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The link between participants' information data and the code will be kept confidential by the NUS research team or a trusted third party. Research data and results will only be collated in its coded format. All research data collected will be retained for a minimum of 10 years following the NUS Research Data Management Policy.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .